James E. Krook

19.0k total citations · 5 hit papers
136 papers, 14.6k citations indexed

About

James E. Krook is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, James E. Krook has authored 136 papers receiving a total of 14.6k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 27 papers in Cancer Research. Recurrent topics in James E. Krook's work include Cancer Treatment and Pharmacology (38 papers), Lung Cancer Research Studies (29 papers) and Colorectal Cancer Treatments and Studies (27 papers). James E. Krook is often cited by papers focused on Cancer Treatment and Pharmacology (38 papers), Lung Cancer Research Studies (29 papers) and Colorectal Cancer Treatments and Studies (27 papers). James E. Krook collaborates with scholars based in United States, Canada and Switzerland. James E. Krook's co-authors include David Harrington, Junming Zhu, Joan H. Schiller, Corey J. Langer, David H. Johnson, Chandra P. Belani, Alan Sandler, Harry S. Wieand, J A Mailliard and C G Moertel and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Annals of Internal Medicine.

In The Last Decade

James E. Krook

134 papers receiving 14.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

2002 4.1k citations James E. Krook et al. profile →
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma

1991 1.4k citations James E. Krook, Harry S. Wieand et al. profile →
Improving Adjuvant Therapy for Rectal Cancer by Combining Protracted-Infusion Fluorouracil with Radiation Therapy after Curative Surgery

1994 820 citations Harry S. Wieand, James E. Krook et al. profile →
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

1989 725 citations Harry S. Wieand, Stephen A. Cullinan et al. Journal of Clinical Oncology profile →
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic.

1989 526 citations John A. Laurie, Harry S. Wieand et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
James E. Krook	10.2k	5.8k	3.1k	2.5k	1.6k	136	14.6k
John J. Crowley	8.0k 0.8×	8.8k 1.5×	2.0k 0.6×	3.9k 1.6×	1.8k 1.1×	195	17.8k
David G. Pfister	8.9k 0.9×	7.2k 1.2×	5.9k 1.9×	2.8k 1.1×	1.9k 1.1×	328	19.3k
Hans‐Joachim Schmoll	9.8k 1.0×	4.6k 0.8×	7.5k 2.4×	3.7k 1.5×	1.3k 0.8×	541	19.2k
Hedy L. Kindler	8.4k 0.8×	7.3k 1.3×	1.8k 0.6×	3.6k 1.4×	3.1k 1.9×	400	16.1k
Marianna Zahurak	6.8k 0.7×	5.0k 0.9×	5.7k 1.8×	3.5k 1.4×	2.1k 1.3×	221	16.8k
Shaker R. Dakhil	9.2k 0.9×	5.1k 0.9×	1.4k 0.5×	3.3k 1.3×	3.1k 1.9×	313	16.4k
Patrick Schöffski	9.6k 0.9×	9.5k 1.6×	3.2k 1.0×	4.8k 2.0×	2.2k 1.4×	510	19.4k
Donna Hollis	5.9k 0.6×	4.6k 0.8×	3.0k 1.0×	1.3k 0.5×	1.5k 0.9×	154	11.4k
Jacek Jassem	11.4k 1.1×	8.0k 1.4×	3.3k 1.1×	4.8k 1.9×	3.9k 2.4×	523	19.9k
Tanios Bekaii‐Saab	8.1k 0.8×	3.3k 0.6×	4.0k 1.3×	3.1k 1.2×	2.3k 1.4×	569	12.7k

Countries citing papers authored by James E. Krook

Since Specialization

Citations

This map shows the geographic impact of James E. Krook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James E. Krook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James E. Krook more than expected).

Fields of papers citing papers by James E. Krook

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James E. Krook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James E. Krook. The network helps show where James E. Krook may publish in the future.

Co-authorship network of co-authors of James E. Krook

This figure shows the co-authorship network connecting the top 25 collaborators of James E. Krook. A scholar is included among the top collaborators of James E. Krook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James E. Krook. James E. Krook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Qi, Yingwei, Steven E. Schild, Sumithra J. Mandrekar, et al.. (2009). Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 4(9). 1075–1082. 52 indexed citations

Mandrekar, Sumithra J., Donald W. Northfelt, Steven E. Schild, et al.. (2006). Impact of Pretreatment Factors on Adverse Events: A Pooled Analysis of North Central Cancer Treatment Group Advanced Stage Non-small Cell Lung Cancer Trials. Journal of Thoracic Oncology. 1(6). 556–563. 10 indexed citations

Delaunoit, Thierry, Steven R. Alberts, Daniel J. Sargent, et al.. (2005). Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Annals of Oncology. 16(3). 425–429. 120 indexed citations

Marks, Randolph S., David L. Graham, Jeff A. Sloan, et al.. (2003). . American Journal of Clinical Oncology. 26(4). 336–337. 6 indexed citations

Marks, Randolph S., David L. Graham, Jeff A. Sloan, et al.. (2003). A Phase II Study of the Dolastatin 15 Analogue LU 103793 in the Treatment of Advanced Non–Small-Cell Lung Cancer. American Journal of Clinical Oncology. 26(4). 336–337. 31 indexed citations

Alberts, Steven R., P. Townley, Richard M. Goldberg, et al.. (2003). Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Groupphase II study. Annals of Oncology. 14(4). 580–585. 52 indexed citations

Markovic, Svetomir N., Vera J. Suman, Robert J. Dalton, et al.. (2002). Randomized, Placebo-Controlled, Phase III Surgical Adjuvant Clinical Trial of Megestrol Acetate (Megace) in Selected Patients With Malignant Melanoma. American Journal of Clinical Oncology. 25(6). 552–556. 9 indexed citations

Alberts, Steven R., P. Townley, Richard M. Goldberg, et al.. (2002). Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Annals of Oncology. 13(4). 553–557. 24 indexed citations

Pandya, Kishan J., B.Y. Yeap, Louis M. Weiner, et al.. (2001). Megestrol and Tamoxifen in Patients With Advanced Endometrial Cancer. American Journal of Clinical Oncology. 24(1). 43–46. 44 indexed citations

10.

Burch, Patrick A., Georgene Schroeder, Joseph Rubin, et al.. (1999). North Central Cancer Treatment Group Phase II Study of 5-Fluorouracil and High-Dose Levamisole for Gastric and Gastroesophageal Cancer Using Survival as the Primary Endpoint of Efficacy. American Journal of Clinical Oncology. 22(5). 505–505. 3 indexed citations

11.

Creagan, Edward T., Vera J. Suman, Suresh Nair, et al.. (1998). Combined Levamisole With Recombinant Interleukin-2 (IL-2) in Patients With Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology. 21(2). 139–141. 8 indexed citations

12.

Elliott, Thomas E., Robert P. Dinapoli, Judith R. OʼFallon, et al.. (1997). Randomized trial of radiation therapy (RT) plus dibromodulcitol (DBD) versus RT plus BCNU in high grade astrocytoma. Journal of Neuro-Oncology. 33(3). 239–250. 22 indexed citations

13.

Gelber, R.D., Aron Goldhirsch, Bernard F. Cole, et al.. (1996). A Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Adjuvant Radiation Therapy and Chemotherapy for Resectable Rectal Cancer. JNCI Journal of the National Cancer Institute. 88(15). 1039–1045. 95 indexed citations

14.

Earle, John D., John Foley, Harry S. Wieand, et al.. (1994). Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. International Journal of Radiation Oncology*Biology*Physics. 28(1). 207–211. 20 indexed citations

15.

Jett, James R., John Q. Su, James E. Krook, Robert M. Goldberg, & J. W. Kugler. (1994). Measurable or assessable disease in lung cancer trials: does it matter?. Journal of Clinical Oncology. 12(12). 2677–2681. 15 indexed citations

16.

Pisansky, Thomas M., James N. Ingle, Daniel J. Schaid, et al.. (1993). Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Impact of clinical, histopathologic, and flow cytometric factors. Cancer. 72(4). 1247–1260. 77 indexed citations

17.

Jett, James R., Lloyd K. Everson, Terry M. Therneau, et al.. (1990). Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.. Journal of Clinical Oncology. 8(1). 33–38. 47 indexed citations

18.

Ingle, James N., J A Mailliard, Daniel J. Schaid, et al.. (1989). Randomized Trial of Doxorubicin Alone or Combined with Vincristine and Mitomycin C in Women with Metastatic Breast Cancer. American Journal of Clinical Oncology. 12(6). 474–480. 14 indexed citations

19.

Everson, Lloyd K., James R. Jett, Judith R. OʼFallon, et al.. (1989). Alternating Chemotherapy With or Without VP-16 in Extensive-Stage Small-Cell Lung Cancer. American Journal of Clinical Oncology. 12(4). 339–344. 8 indexed citations

20.

Edmonson, J H, James E. Krook, George D. Malkasian, et al.. (1987). Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecologic Oncology. 28(1). 20–24. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact